P-285 A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Andrew, Zhu, Peter, Galle, Masatoshi, Kudo, Richard, Finn, Ling, Yang, Paolo, Abada, Josep, Llovet
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984072/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw199.275
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars